Comparative Pharmacology
Head-to-head clinical analysis: ANGIOVIST 282 versus ANGIOVIST 370.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANGIOVIST 282 versus ANGIOVIST 370.
ANGIOVIST 282 vs ANGIOVIST 370
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Angiovist 282 (diatrizoate meglumine and diatrizoate sodium) is a radiographic contrast agent that contains iodine, which attenuates X-rays, allowing visualization of vascular structures and organs. It increases the contrast between blood vessels and surrounding tissues by absorbing X-rays.
Angiovist 370 (diatrizoate meglumine) is a water-soluble iodinated radiographic contrast agent that attenuates X-rays, thereby enhancing the contrast of vascular structures and organs during imaging procedures.
Iohexol (ANGIOVIST 282) is a nonionic iodinated contrast medium. Typical adult dose: 50-200 mL intravenously or intra-arterially, depending on procedure (e.g., CT: 75-150 mL IV).
Intravenous injection: 1-2 mL/kg (370 mg I/mL) up to 150 mL total for CT imaging; intra-arterial injection: 5-80 mL depending on procedure. Rate: 1-5 mL/sec.
None Documented
None Documented
Terminal elimination half-life: 1.5–2 hours in patients with normal renal function; prolonged in renal impairment.
Terminal elimination half-life approximately 2 hours; prolonged in renal impairment (up to 30-40 hours in severe impairment).
Renal excretion via glomerular filtration; unchanged drug: >95% within 24 hours. Biliary/fecal: <5%.
Primarily renal excretion of unchanged drug via glomerular filtration; approximately 95% eliminated in urine within 24 hours, with less than 1% biliary/fecal.
Category C
Category C
Contrast Agent
Contrast Agent